{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:01:53Z","timestamp":1787162513041,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Five-field 130\u00b0 wide-angle imaging is the standard of care for retinopathy of prematurity (ROP) screening with an ideal hypothetical composite field-of-view (FOV) of 180\u00b0. We hypothesized that in many real-world scenarios the effective composite FOV is considerably less than ideal. This observational retrospective study analyzed the effective FOV of fundus photos of patients screened for ROP as part of the Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP) initiative. Five fundus photos were selected from each eye per image session. Effective FOV was defined as the largest circular area centered on the optic disc that encompassed retina in each of the four cardinal views. Seventy-three subjects were analyzed, 35 without ROP and 34 with ROP. Mean effective FOV was 144.55\u2009\u00b1\u20096.62\u00b0 ranging from 130.00 to 153.71\u00b0. Effective FOV was not correlated with the presence or absence of ROP, gestational age, birth weight, or postmenstrual age. Mean effective FOV was wider in males compared to females. Standard five-field 130\u00b0 fundus photos yielded an average effective FOV of 144.54\u00b0 in the SUNDROP cohort. This implies that an imaging FOV during ROP screening considerably less than the hypothetical ideal of 180\u00b0 is sufficient for detecting treatment warranted ROP.<\/jats:p>","DOI":"10.1038\/s41598-022-22964-w","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T06:02:36Z","timestamp":1668146556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effective field of view of wide-field fundus photography in the Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP)"],"prefix":"10.1038","volume":"12","author":[{"given":"Marco H.","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moosa","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Bodnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Kumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius M.","family":"Moshfeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"22964_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jaapos.2012.09.004","volume":"16","author":"L Kong","year":"2012","unstructured":"Kong, L., Fry, M., Al-Samarraie, M., Gilbert, C. & Steinkuller, P. G. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J. AAPOS 16, 501\u2013507 (2012).","journal-title":"J. AAPOS"},{"key":"22964_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","volume":"128","author":"The Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2010","unstructured":"The Early Treatment for Retinopathy of Prematurity Cooperative Group. Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch. Ophthalmol. 128, 663 (2010).","journal-title":"Arch. Ophthalmol."},{"key":"22964_CR3","doi-asserted-by":"publisher","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","volume":"142","author":"WM Fierson","year":"2018","unstructured":"Fierson, W. M. American academy of pediatrics section on ophthalmology, american academy of ophthalmology, American association for pediatric ophthalmology and strabismus & American association of certified orthoptists. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics 142, e20183061 (2018).","journal-title":"Pediatrics"},{"key":"22964_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/archopht.126.4.493","volume":"126","author":"KM Jackson","year":"2008","unstructured":"Jackson, K. M. et al. Cost-utility analysis of telemedicine and ophthalmoscopy for retinopathy of prematurity management. Arch. Ophthalmol. 126, 493\u2013499 (2008).","journal-title":"Arch. Ophthalmol."},{"key":"22964_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.survophthal.2009.02.020","volume":"54","author":"GM Richter","year":"2009","unstructured":"Richter, G. M., Williams, S. L., Starren, J., Flynn, J. T. & Chiang, M. F. Telemedicine for retinopathy of prematurity diagnosis: Evaluation and challenges. Surv. Ophthalmol. 54, 671\u2013685 (2009).","journal-title":"Surv. Ophthalmol."},{"key":"22964_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3109\/02713683.2012.754902","volume":"38","author":"N Fijalkowski","year":"2013","unstructured":"Fijalkowski, N. et al. Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): Four-years of screening with telemedicine. Curr. Eye Res. 38, 283\u2013291 (2013).","journal-title":"Curr. Eye Res."},{"key":"22964_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3928\/23258160-20140122-01","volume":"45","author":"N Fijalkowski","year":"2014","unstructured":"Fijalkowski, N. et al. Stanford University Network for diagnosis of retinopathy of prematurity (SUNDROP): Five years of screening with telemedicine. Ophthalmic Surg. Lasers Imaging Retin. 45, 106\u2013113 (2014).","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"22964_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1755-3768.2009.01715.x","volume":"88","author":"Y Murakami","year":"2010","unstructured":"Murakami, Y. et al. Stanford university network for diagnosis of retinopathy of prematurity (SUNDROP): 24-month experience with telemedicine screening. Acta Ophthalmol. 88, 317\u2013322 (2010).","journal-title":"Acta Ophthalmol."},{"key":"22964_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3928\/15428877-20100929-08","volume":"42","author":"RA Silva","year":"2011","unstructured":"Silva, R. A., Murakami, Y., Lad, E. M. & Moshfeghi, D. M. Stanford University network for diagnosis of retinopathy of prematurity (SUNDROP): 36-Month experience with telemedicine screening. Ophthalmic Surg. Lasers Imaging 42, 12\u201319 (2011).","journal-title":"Ophthalmic Surg. Lasers Imaging"},{"key":"22964_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jcjo.2014.11.005","volume":"50","author":"SK Wang","year":"2015","unstructured":"Wang, S. K. et al. SUNDROP: Six years of screening for retinopathy of prematurity with telemedicine. Can. J. Ophthalmol. 50, 101\u2013106 (2015).","journal-title":"Can. J. Ophthalmol."},{"key":"22964_CR11","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1167\/iovs.10-7155","volume":"52","author":"A Vinekar","year":"2011","unstructured":"Vinekar, A. et al. Understanding clinically undetected macular changes in early retinopathy of prematurity on spectral domain optical coherence tomography. Investig. Ophthalmol. Vis. Sci. 52, 5183\u20135188 (2011).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"22964_CR12","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2014.1604","volume":"132","author":"GE Quinn","year":"2014","unstructured":"Quinn, G. E. et al. Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity. JAMA Ophthalmol. 132, 1178\u20131184 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"22964_CR13","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1038\/s41598-021-84723-7","volume":"11","author":"TR Rosenblatt","year":"2021","unstructured":"Rosenblatt, T. R. et al. Key factors in a rigorous longitudinal image-based assessment of retinopathy of prematurity. Sci. Rep. 11, 5369 (2021).","journal-title":"Sci. Rep."},{"key":"22964_CR14","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2147\/OPTH.S250361","volume":"14","author":"MH Ji","year":"2020","unstructured":"Ji, M. H., Callaway, N. F., Greven, M. A., Vail, D. & Moshfeghi, D. M. Telemedicine follow-up for intravitreal bevacizumab injection in the Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP) Cohort. Clin. Ophthalmol. 14, 1161\u20131163 (2020).","journal-title":"Clin. Ophthalmol."},{"key":"22964_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/s41433-019-0392-4","volume":"33","author":"MA Greven","year":"2019","unstructured":"Greven, M. A. & Moshfeghi, D. M. Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): Telemedicine-based examination after laser photocoagulation for treatment-warranted retinopathy of prematurity. Eye (Lond). 33, 1347\u20131355 (2019).","journal-title":"Eye (Lond)."},{"key":"22964_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0161-6420(03)00831-5","volume":"110","author":"AL Ells","year":"2003","unstructured":"Ells, A. L. et al. Telemedicine approach to screening for severe retinopathy of prematurity: A pilot study. Ophthalmology 110, 2113\u20132117 (2003).","journal-title":"Ophthalmology"},{"key":"22964_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner, H. A., Kennedy, K. A. & Chuang, A. Z. Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. N. Engl. J. Med. 364, 603\u2013615 (2011).","journal-title":"N. Engl. J. Med."},{"key":"22964_CR18","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl, A. et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial. Lancet (London, England) 394, 1551\u20131559 (2019).","journal-title":"Lancet (London, England)"},{"key":"22964_CR19","volume-title":"Facts and Figures Concerning the Human Retina Webvision: The Organization of the Retina and Visual System","author":"H Kolb","year":"1995","unstructured":"Kolb, H. Facts and Figures Concerning the Human Retina Webvision: The Organization of the Retina and Visual System (University of Utah Health Sciences Center, 1995)."},{"key":"22964_CR20","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.1364\/BOE.433775","volume":"12","author":"X Yao","year":"2021","unstructured":"Yao, X., Toslak, D., Son, T. & Ma, J. Understanding the relationship between visual-angle and eye-angle for reliable determination of the field-of-view in ultra-wide field fundus photography. Biomed. Opt. Express 12, 6651\u20136659 (2021).","journal-title":"Biomed. Opt. Express"},{"key":"22964_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","volume":"142","author":"JT Flynn","year":"2006","unstructured":"Flynn, J. T. & Chan-Ling, T. Retinopathy of prematurity: Two distinct mechanisms that underlie zone 1 and zone 2 disease. Am. J. Ophthalmol. 142, 46-59.e2 (2006).","journal-title":"Am. J. Ophthalmol."},{"key":"22964_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/eye.1994.101","volume":"8","author":"DE Laws","year":"1994","unstructured":"Laws, D. E., Haslett, R., Ashby, D., O\u2019brien, C. & Clark, D. Axial length biometry in infants with retinopathy of prematurity. Eye 8, 427\u2013430 (1994).","journal-title":"Eye"},{"key":"22964_CR23","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/eye.1994.163","volume":"8","author":"C O\u2019brien","year":"1994","unstructured":"O\u2019brien, C. & Clark, D. Ocular biometry in pre-term infants without retinopathy of prematurity. Eye 8, 662\u2013665 (1994).","journal-title":"Eye"},{"key":"22964_CR24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/bjo.55.8.538","volume":"55","author":"VP Emiru","year":"1971","unstructured":"Emiru, V. P. Response to mydriatics in the African. Br. J. Ophthalmol. 55, 538\u2013543 (1971).","journal-title":"Br. J. Ophthalmol."},{"key":"22964_CR25","first-page":"669","volume":"67","author":"J Cooper","year":"1996","unstructured":"Cooper, J. et al. Pupillary dilation and funduscopy with 1.0% hydroxyamphetamine plus 0.25% tropicamide (Paremyd) versus tropicamide (0.5 or 1.0%) as a function of iris and skin pigmentation, and age. J. Am. Optom. Assoc. 67, 669\u2013675 (1996).","journal-title":"J. Am. Optom. Assoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22964-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22964-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22964-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T06:07:40Z","timestamp":1668146860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22964-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22964"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22964-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"27 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H.J., None; M.Z., None; Z.B, Ainsly (Consultant, Equity); S.K.W., None; J.K., Pr3vent INC (F,CEO); D.M.M, Ainsly (Consultant, equity), Alexion (Consultant), Apellis (PI), Bayer Pharma AG (SC,C), dSentz, Inc. (Founder,Equity,BOD), Genentech (grant support), Grand Legend Technology, LTD (Equity), Pr3vent INC (founder,Equity,BOD), Prime Medical Education (C), Promisight, Inc (Founder,Equity,BOD), Pykus (Equity,SAB), Regeneron (Steering Committee), SLACK, Inc (C), Vindico (C), Visunex (Equity).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19276"}}